Kim Wai Yu Selected Research

Hormones (Hormone)

4/2018	A single institution experience with palbociclib toxicity requiring dose modifications.
2/2015	Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kim Wai Yu Research Topics

Disease

2	Infections 01/2020 - 12/2014
2	Breast Neoplasms (Breast Cancer) 04/2018 - 12/2014
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2020
1	Abscess 01/2020
1	Neutropenia 04/2018
1	Adenocarcinoma of Lung 01/2018
1	Disease Progression 01/2018
1	Pathologic Complete Response 02/2015
1	Triple Negative Breast Neoplasms 02/2015
1	Neoplasms (Cancer) 02/2015

Drug/Important Bio-Agent (IBA)

3	Trastuzumab (Herceptin)FDA Link 01/2020 - 12/2014
2	pertuzumabIBA 01/2020 - 12/2014
2	Hormones (Hormone)IBA 04/2018 - 02/2015
1	palbociclibIBA 04/2018
1	human ERBB2 proteinIBA 04/2018
1	osimertinibIBA 01/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018
1	Growth Factor ReceptorsIBA 01/2018
1	PlatinumIBA 02/2015
1	Carboplatin (JM8)FDA LinkGeneric 02/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2015
1	AnthracyclinesIBA 02/2015
1	taxaneIBA 02/2015

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2020 - 12/2014
2	Therapeutics 04/2018 - 12/2014
1	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2020
1	Drug Tapering 04/2018
1	Neoadjuvant Therapy 02/2015
1	Treatment Delay 12/2014